Related Experiment Video
Updated: Jun 21, 2026
09:37
Navigating MARRVEL, a Web-Based Tool that Integrates Human Genomics and Model Organism Genetics Information
Published on: August 15, 2019
Gaucher disease: a model disorder for biomarker discovery
Rolf G Boot1, Mariëlle J van Breemen, Wouter Wegdam
1Department of Medical Biochemistry, Academic Medical Center, University of Amsterdam, Meibergdreef 15, 1105 AZ Amsterdam, The Netherlands. r.g.boot@amc.uva.nl
Expert Review of Proteomics
|August 18, 2009
Summary
Gaucher disease biomarkers are crucial for monitoring disease progression and treatment effectiveness. This review discusses current biomarkers and novel proteomic approaches for Gaucher disease management.
Area of Science:
- Biochemistry
- Genetics
- Medical Research
Background:
- Gaucher disease is a genetic lysosomal storage disorder caused by deficient glucocerebrosidase activity.
- This deficiency leads to the accumulation of glucosylceramide-laden macrophages in organs like the spleen, liver, and bone marrow.
- Effective therapies like enzyme-replacement and substrate-reduction therapies exist, necessitating reliable monitoring tools.
Purpose of the Study:
- To review existing biomarkers for Gaucher disease.
- To discuss the current application of biomarkers in clinical management.
- To explore the use of proteomic technologies for identifying new Gaucher biomarkers.
Main Methods:
- Literature review of existing data on Gaucher disease biomarkers.
- Analysis of current clinical applications of these biomarkers.
- Review of modern proteomic technologies for biomarker discovery.
Main Results:
- Existing biomarkers are used to monitor disease onset, progression, and therapeutic efficacy.
- Storage cells play a key role in Gaucher pathology, making them targets for biomarker research.
- Proteomic technologies offer promising avenues for identifying novel and improved biomarkers.
Conclusions:
- Biomarkers are essential for managing Gaucher disease and evaluating treatment success.
- Continued research into novel biomarkers, particularly using proteomic approaches, is vital.
- Improved biomarkers will enhance patient care and therapeutic strategies for Gaucher disease.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:11Genome-wide Association Studies-GWAS
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...